Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer

Abstract

The results of our study indicate the feasibility and the potential benefit of a protocol including systemic chemotherapy, surgical cytoreduction and HIPEC in patients with peritoneal carcinomatosis from ovarian cancer. A phase III trial to compare this approach with conventional treatment is needed.

Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review

“…Argenta et al 55 reported a grade III to IV morbidity of 30%, with the adverse events reported being 1 instance of grade III acute renal injury and 2 instances of grade IV thrombocytopenia and neutropenia. In comparison, Delotte et al 77 reported 20% of patients experiencing grade III to IV complications, whereas Roviello et al, 81 with a smaller cohort, reported only 12% of patients experiencing grade III to IV complications. Bakrin et al 76 reported grade III to IV complications in 30% of procedures performed for advanced or recurrent disease without further subgroup analysis.…”

Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis

“…The HIPEC chemotherapy used, temperature and duration was described in all 37 studies (eTable 2). The most commonly used HIPEC chemotherapy was cisplatin (CDDP) that was used either alone [26,42,49,50,55], or in combination with other agents such as doxorubicin [36,37,41,45,56], paclitaxel [40] or mitomycin-C [34,57] Figure 1). Only one study reached median overall survival for CRS with and without HIPEC (64.4 months and 46.4, respectively).…”

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

“…Most of these studies are single institution studies with a limited number of patients. [39][40][41][42][43][44][45][46] and a few are multi institutional studies [47][48][49]. Most of the studies report results of HIPEC for first line and second line therapy together.…”